Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2023-09-22 00:00:00 ET · period of report 2023-09-20 · accession 0001610717-23-000297 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-22 | 2023-09-20 | CTMX | McCarthy Sean A. | CEO, Dir | A - Grant | $0.00 | +40.0K | 445.4K | +10% | $0 | |
| 2023-09-22 | 2023-09-22 | CTMX | McCarthy Sean A. | CEO, Dir | S - Sale | $1.30 | -14.6K | 430.8K | -3% | -$19.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-20 | A | A | 40,000 | $0.00 | 445,356 | D | — | — | (F2) Includes 161,250 restricted stock units. |
| 2 | Common | Common Stock | 2023-09-22 | S | D | 14,601 | $1.30 | 430,755 | D | — | — | (F2) Includes 161,250 restricted stock units. |